Effectiveness and Safety of High-intensity Focused Ultrasound for Bone Tumors:A Systematic Review
Ying-qiang WANG,Xiang-lian LI,You-ping LI,Qian-qian LUO
DOI: https://doi.org/10.7507/1672-2531.20150055
2015-01-01
Abstract:Objective To explore the effectiveness and safety of high-intensity focused ultrasound(HIFU) for bone tumors,so as to provide a reference for clinical decision. Methods Pub Med,EMbase,The Cochrane Library,CNKI and VIP databases were systematically searched for clinical effectiveness and safety studies of HIFU for bone tumors up to August 2014. Study selection,data extraction and quality assessment were applied independently by two reviewers,and then Rev Man 5.1 software was used for conducting meta-analysis. If the data cannot be synthesized,the research outcome was described with a qualitative analysis. Results A total of 10 case series including 257 patients(157 males,100 females) were included. The current evidence indicated that overall survival rates for all primary bone malignancy at 1-,2-,3- and 5-year were 89.8%,72.3%,60.5% and 50.5%,respectively. For the patients with clinical stage IIb,the rates were 93.3%,82.4%,75% and 63.7%,respectively. For those with clinical stage III,the rates were 79.2%,42.2%,21.1% and 15.8%,respectively. The local recurrence rate of HIFU for bone tumors was 7% to 9%,and recurrences at 1-,2-,3- and 5-year were 0%,6.2%,11.8% and 11.8%,respectively. The amputation rate was 2% to 7%. The adverse reaction rate was 27.2%(70/257),and among them the main was mild skin burn(21/257,8.2%),followed by I degree burns(16/257,6.2%),nerve damage(10/257,3.9%) and fracture(6/257,2.3%). Conclusion HIFU provide an alternative choice for patients with bone malignancy,with a certain effectiveness and safety. However,high-quality,large-scale randomized controlled trials or cohort studies which may focus on vary kinds of tumors,clinical stage and site of lesions are urgently needed,so that clinicians can use sufficient evidence for their clinical decision-making.